Groundbreaking cross-border collaboration with Tokyo-based ModAstera Inc.

Exciting news! We are thrilled to announce a groundbreaking cross-border collaboration between Taiwan’s medical hardware expertise and Japan’s software innovation.
.
Wellgen Medical has officially partnered with Tokyo-based ModAstera Inc. to redefine the speed and precision of clinical diagnostics on metastatic cancers.
.
Through this joint Intellectual Property agreement, Wellgen is combining our advanced AI-assisted 3D tomographic microscopy and clinical image datasets with ModAstera’s MAEA (Medical AI Engineering Agent), an end-to-end medical AI development platform that compresses model development timelines from months to days.
.
This synergy is driving the future of EdgeAI directly at the point of care, ensuring ultra-low latency and data privacy. By leveraging ModAstera's MAEA platform to automate AI model development, we can bridge the gap between clinical domain expertise and advanced machine learning. Together, we are making the next generation of medical diagnostic tools smarter, more accurate, and more accessible for healthcare systems worldwide.